30 completed, 5 active not recruiting, 5 unknown, 2 not yet recruiting. 46 Phase 1, 16 Phase 2.
Follow Staphylococcal Infections: new trials by email Literature Review of Staphylococcal Infections trials Research Report on Staphylococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus Topical anti-Staphylococcus bacteriophage therapy, Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy - Diabetic Foot, Staphylococcal Infections | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nīmes | 60 | 2026-09-01 | 2026-03-20 |
| Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics - CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection | Phase 1 | Not yet recruiting | University of California, San Diego | 30 | 2025-12-31 | 2025-12-12 |
| Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment Nasal Microbiota Transplant (NMT), Placebo - Staphylococcal Aureus Infection, Microbial Colonization | Phase 1 | Recruiting | Johns Hopkins University | 175 | 2025-08-27 | 2026-08-10 |
| A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) AZD7760, Placebo - Staphylococcus Aureus | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 242 | 2024-12-30 | 2026-10-28 |
| Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection Phage therapy - Prosthetic Joint Infections of Hip, Staphylococcus Aureus Infection | Phase 1 / Phase 2 | Active not recruiting | University of Calgary | 1 | 2024-11-20 | 2025-06-11 |
| Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome Nasal Microbiota Transplant (NMT), Placebo - Staphylococcus Aureus, Microbial Colonization | Phase 1 | Active not recruiting | Johns Hopkins University | 78 | 2024-09-03 | 2026-09-04 |
| First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133 HY_133, Placebo - Staphylococcus Aureus | Phase 1 | Recruiting | University Hospital Tuebingen | 52 | 2024-07-10 | 2024-12-06 |
| Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study Mupirocin (50 mg), Mupirocin (500 mg), blood samples after Single dose part - Healthy, Staphylococcus Aureus Infection | Phase 1 | Active not recruiting | Centre Hospitalier Universitaire de Saint Etienne | 40 | 2024-02-29 | 2025-07-03 |
| Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis Extra-Virgin Coconut Oil - Lactation Mastitis, Breast Feeding | Phase 1 | Unknown | Texas Woman's University | 100 | 2023-11-06 | 2024-03-27 |
| Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® IMP, Placebo - Surgical Site Infection, Staphylococcus Aureus Infection | Phase 1 / Phase 2 | Unknown | MB PHARMA s.r.o. | 52 | 2023-10-27 | 2024-03-19 |
| Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant nasal microbiota transplant (NMT), Placebo - Staphylococcus Aureus, Microbial Colonization | Phase 1 | Active not recruiting | Johns Hopkins University | 34 | 2023-10-25 | 2025-12-11 |
| Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia AP-SA02, Placebo - Bacteremia, Staphylococcus Aureus | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 56 | 2022-04-26 | 2026-03-23 |
| Phage Therapy for the Prevention and Treatment of Pressure Ulcers. Bacteriophage-loaded Microcapsule Spray, Placebo, Standard of Care - Pressure Ulcer | Phase 1 / Phase 2 | Unknown | Precisio Biotix Therapeutics, Inc. | 69 | 2022-01-01 | 2021-12-21 |
| Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients Bacteriophage cocktail spray, Xeroform - Wound Infection | Phase 1 | Unknown | Precisio Biotix Therapeutics, Inc. | 12 | 2022-01-01 | 2021-12-22 |
| A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection 9MW1411 injection, 9MW1411 injection placebo - Staphylococcus Aureus Infection | Phase 1 | Completed | Mabwell (Shanghai) Bioscience Co., Ltd. | 42 | 2021-04-16 | 2022-06-15 |
| Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers TP-102 - Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection | Phase 1 / Phase 2 | Completed | Technophage, SA | 20 | 2021-03-22 | 2022-10-04 |
| A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7 - Staphylococcus Aureus Infection | Phase 1 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 144 | 2019-05-16 | 2021-03-30 |
| Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Hydroxychloroquine - Hidradenitis Suppurativa, Hidradenitis | Phase 1 / Phase 2 | Completed | Elena Gonzalez Brant, MD | 17 | 2017-09-28 | 2020-04-02 |
| Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis Roseomonas mucosa - Atopic Dermatitis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 31 | 2017-04-20 | 2019-11-27 |
| A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml), Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml), High dosage of Staphylococcus aureus vaccine (60µg/0.6ml) - Staphylococcus Aureus Infection | Phase 1 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 144 | 2016-09-01 | 2017-10-17 |
Showing 20 of 46. Sign in to see all of them.
Staphylococcal Skin Infections (6) · Pseudomonas Infections (4) · Streptococcal Infections (4) · Bacteremia (3) · Bacterial Infections (3) · Communicable Diseases (3) · Candidiasis (2) · Cellulitis (2) · Diabetic Foot (2) · Furunculosis (2) · Soft Tissue Infections (2) · Wound Infection (2) · Acinetobacter Infections (1) · Breast Feeding (1)
Bacterial Infections and Mycoses (46) · Gram-Positive Bacterial Infections (46) · Infections (45) · Bacterial Infections (43) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Skin Diseases, Bacterial (9) · Skin Diseases, Infectious (9) · Inflammation (7) · Gram-Negative Bacterial Infections (5) · Systemic Inflammatory Response Syndrome (5) · Disease Attributes (4)
Blood Specimen Collection (4) · ceftobiprole (4) · Mupirocin (2) · V710 vaccine (2) · 2,4,6-tribromophenol (1) · Adjuvants, Pharmaceutic (1) · Aluminum Hydroxide (1) · Gramicidin, Neomycin Sulfate, Nystatin, Triamcinolone Acetonide Drug Combination (1) · Hydroxychloroquine (1) · Inosine Monophosphate (1) · Ointments (1) · Phage Therapy (1) · Sodium Chloride (1) · Standard of Care (1) · Textiles (1)
Basilea Pharmaceutica (4) · Pfizer (4) · Johns Hopkins University (3) · Merck Sharp & Dohme LLC (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Jiangsu Province Centers for Disease Control and Prevention (2) · NovaDigm Therapeutics, Inc. (2) · Precisio Biotix Therapeutics, Inc. (2) · AM-Pharma (1) · Aridis Pharmaceuticals, Inc. (1) · Armata Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Centre Hospitalier Universitaire de Nīmes (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Destiny Pharma Plc (1)
United States (20) · China (3) · France (3) · Australia (2) · Belgium (2) · Canada (1) · Czechia (1) · Germany (1) · Israel (1) · Netherlands (1) · Philippines (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Aaron M Milstone, MD (1) · Aaron Milstone (1) · Aaron Milstone, MD (1) · Albert Sotto, MD, PhD (1) · Deborah Birx, MD (1) · Elena M Gonzalez Brant, MD (1) · Fangyue Meng, Master (1) · Gina Suh, M.D. (1) · Hasan Jafri, M.D. (1) · Hector Bolivar, M.D. (1) · Howard Schwartz, M.D. (1)
PMID 31993453, PMID 35473663, PMID 12672715, PMID 17651080, PMID 17893153, PMID 19134433, PMID 20523108, PMID 20943877, PMID 22192849, PMID 25707693, PMID 25715157, PMID 27477840, PMID 27519620, PMID 27707765, PMID 27866765, PMID 27916408, PMID 28143674, PMID 28418698, PMID 28564614, PMID 29299430, PMID 30343314, PMID 30935548, PMID 32602684, PMID 33873093, PMID 39740667, PMID 9017547
2023 (1), R21AI179644 (1)